This meta‐analysis aims to clarify the role of the EGFR‐plasma test in prognosis for non‐small cell lung cancer (NSCLC) who have mutant tumors and receive EGFR tyrosine kinase inhibitors (TKIs). Here, EGFR is linked to lung cancer.